Moderna to Present at Upcoming Conferences in November 2023
CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming...
Vaccine
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
The Company demonstrates how its integrated Artificial Intelligence ecosystem accelerates innovation at scale and creates value across the enterpriseModerna to...
New Real-World Data Show TREMFYA® (guselkumab) Was Associated With Clinically Meaningful Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis
People living with treatment-resistant active psoriatic arthritis reported meaningful improvements in pain, physical function and fatigue on guselkumab through six...
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
Icosavax to Participate in the Jefferies London Healthcare Conference
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)...
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30...
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one...
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or...
SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent...
Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Potential to address cancer treatment related Cytokine Release SyndromeLONDON, UK / ACCESSWIRE / November 3, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),...
Renalogic Receives Second Consecutive Savings Certification From the Validation Institute for Dialysis Claims Repricing
Self-funded plans save 84.5% compared with their ‘Allowed Amount' when using Renalogic's ImpactProtect service.CHICAGO, IL / ACCESSWIRE / November 2,...
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to...
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves...
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer...
DHSS launches interactive statewide flu dashboard
Flu season officially started October 1JEFFERSON CITY, Mo., Oct. 13, 2023 (GLOBE NEWSWIRE) -- The Missouri Department of Health and...
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live...
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD – The Liver Meeting® 2023
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new...
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,...